Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 199 results for "lacosamide"

UCB and Daiichi Sankyo will jointly commercialize lacosamide in Japan
Finchannel.com

Japanese MHLW approves lacosamide as adjunctive therapy to tre...

Daiichi Sankyo Company, Limited and UCB Biopharma SPRL (UCB) announced the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted approval for lacosamide (brand name Vimpat) as an adjunctive therapy in the treatment of partial onset ... PharmaBiz, 2 weeks ago

15 images for lacosamide

Finchannel.com, 2 weeks ago
Pharmafile, 2 weeks ago
Edu Bourse, 2 weeks ago
Monthly Prescribing Reference, 4 weeks ago
Edu Bourse, 1 month ago
Monthly Prescribing Reference, 3 months ago
Money Control, 2 months ago
India Infoline, 2 months ago
Central Chronicle, 2 months ago
Money Control, 2 months ago

UCB, Daiichi Sankyo receive Japanese approval for additional indication of lacosamide

Singapore: Daiichi Sankyo Company Limited and Brussels' UCB Biopharma SPRL has announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted approval for lacosamide (brand name VIMPAT) as an adjunctive therapy in the treatment ...
 Bio Spectrum Asia2 weeks ago
Pharmafile

UCB scores Japanese approval for seizure therapy, Vimpat

UCB Biopharma (EURONEXT: UCB) and Daiichi Sankyo have announced that Vimpat (lacosamide) has been approved as an adjunctive therapy in the treatment of partial onset seizures in adult patients with epilepsy in Japan. Vimpat is approved in this ...
 Pharmafile2 weeks ago BRIEF-UCBs Vimpat gets Japanese approval  Reuters UK2 weeks ago
Edu Bourse

BRIEF-UCB announces new clinical trial data on lacosamide

May 30 UCB SA : * Says new clinical trial data, presented at the second Congress of the European Academy of Neurology, showed non-inferiority of lacosamide (VIMPAT) monotherapy compared with controlled-release carbamazepine among patients with ...
 Reuters UK1 month ago Positive VIMPAT® (lacosamide) monotherapy Phase III trial results presented at European Academy o...  Edu Bourse1 month ago Positive VIMPAT (lacosamide) monotherapy Phase III trial results presented at European Academy of Neurology Congress  FirstWord Pharma1 month ago
India Infoline

Breckenridge Pharmaceutical, Inc. Announces Final ANDA Approval for Lacosamide Tablets Vimpat

By a News Reporter-Staff News Editor at Drug Week Breckenridge Pharmaceutical, Inc. announced that Breckenridge and MSN Laboratories Private Limited were granted final approval for their ANDA lacosamide tablets, 50 mg, 100 mg, 150 mg and 200 mg. a ...
 Pharmacy Choice2 months ago Marksans gets USFDA approval and other top pharma news  India Infoline2 months ago Alembic Pharmaceuticals receives final approval for Lacosamide Tablets  Business Standard2 months ago Alembic Pharma receives USFDA approval for Lacosamide tablets  Myiris2 months ago
[x]  

Efficacy, safety, and tolerability of lacosamide in patients with gain-of-function Na v 1.7 mutation-related small fiber neuropathy: study protocol of a randomized controlled trialthe LENSS study

Home » Health » Efficacy, safety, and tolerability of lacosamide in patients with gain-of-function Na v 1.7 mutation-related small fiber neuropathy: study protocol of a randomized controlled trialthe LENSS study / no comments b.i.d., ...
 HealthMediciNet.com3 weeks ago
Monthly Prescribing Reference

Study Examines QoL/Mood Outcomes of Adjunct Seizure Therapy, Lacosamide

A 28-week open-label study of the adjunct antiepileptic drug, lacosamide, showed that it had a low risk of adverse mood effects and a low risk for overall effect on cognition. Similar to prior studies, this study also found a significant reduction ...
 Monthly Prescribing Reference4 weeks ago

Patent Issued for Process for the Preparation of Lacosamide and Its Novel Intermediate (USPTO 9346744)

By a News Reporter-Staff News Editor at -- Rao; Davuluri Ramamohan (Hyderabad, IN) has been issued patent number 9346744, according to news reporting originating out of Alexandria, Virginia, by VerticalNews editors. The patent's inventors are ...
 Equities.com1 month ago

Generic pressures will drive down UCB's pharmaceutical sales after short-term growth

Datamonitor Healthcare forecasts that UCB's prescription pharmaceutical sales will rise during the initial part of the forecast period to a peak of $5.3bn in 2021. This will be driven by expanding market share of Cimzia (certolizumab) and Vimpat ...
 DataMonitor HealthCare2 days ago

Court Report - July 2016

About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Eli Lilly and Company et al. v. Apotex Inc. et al. 1:16-cv-00475; filed June 22, 2016 in the District Court of Delaware • Plaintiffs: Eli Lilly and ...
 JD Supra5 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - lacosamide
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less